NEW YORK (GenomeWeb) – PerkinElmer said today that it has priced an offering of €300 million ($368 million) aggregate principal amount of 0.6 percent senior notes due 2021.
The issuance of the notes is expected to close on April 11, subject to customary closing conditions. The notes will pay interest on an annual basis.
PerkinElmer plans to use the net proceeds of the offering to repay the $200 million aggregate principal amount outstanding under its term loan facility and to repay a portion of the aggregate principal amount outstanding under its revolving credit facility incurred to pay a portion of its approximately $1.3 billion acquisition of Euroimmun Medical Laboratory Diagnostics, which closed in December.
PerkinElmer expects to use any remaining proceeds for general corporate purposes.
JP Morgan is acting as book-running manager for the offering.